Biochemical recurrence | With Steve Freedland

A fantastic episode for urologists, radiation oncologists, and anyone interested in localised prostate cancer. Biochemical recurrence (BCR) is unfortunately all too common after surgery or radiation for prostate cancer, and today we talk with someone who has been working in BCR for more than 20 years. Dr Steve Freedland, Urologist at Cedars-Sinai in Los Angeles, popped into the GU Cast studio to talk about the landmark series from Johns-Hopkins Medical Institute (links below) which still today remains our best guide to the natural history of BCR after radical prostatectomy. And the key message that PSA doubling time is our most important tool to risk stratify patients reminds true today. And Steve of course is the lead investigator of the EMBARK trial, published in NEJM in 2023, which has led to a new standard of care for men experiencing high-risk BCR after surgery or radiotherapy. EMBARK has clearly shown us that the use of enzaluamide, either on its own, or with androgen deprivation therapy, reduces the risk of metastases when compared with ADT alone. We dive deep into EMBARK with Steve.This is a Themed Podcast supported by our Gold Partners, Astellas. Astellas also supported Steve to be in Australia this week for the USANZ ASM in Perth, and visits to Melbourne and Sydney. Your hosts are Professor Declan Murphy and Dr Renu Eapen. Even better on our Youtube channelLinks:Freedland et al JAMA 2005 EMBARK paper in NEJM